842144-06-3

Basic information

• Product Name: (E)-7-broMo-4-chloro-1-ethyl-N-hydroxy-1H-iMidazo[4,5-c]pyridine-2-carbiMidoyl cyanide
• Synonyms: (E)-7-broMo-4-chloro-1-ethyl-N-hydroxy-1H-iMidazo[4,5-c]pyridine-2-carbiMidoyl cyanide;(7-Bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)hydroxyiminoacetonitrile
• CAS NO: 842144-06-3
• Molecular Formula: C10H7BrClN5O
• Molecular Weight: 328.55248
• Mol File: 842144-06-3.mol

Chemical Properties

• Boiling Point: 522.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.86±0.1 g/cm3(Predicted)
• PKA: 7.20±0.31(Predicted)
• CAS DataBase Reference: (E)-7-broMo-4-chloro-1-ethyl-N-hydroxy-1H-iMidazo[4,5-c]pyridine-2-carbiMidoyl cyanide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-7-broMo-4-chloro-1-ethyl-N-hydroxy-1H-iMidazo[4,5-c]pyridine-2-carbiMidoyl cyanide(842144-06-3)
• EPA Substance Registry System: (E)-7-broMo-4-chloro-1-ethyl-N-hydroxy-1H-iMidazo[4,5-c]pyridine-2-carbiMidoyl cyanide(842144-06-3)

Safety Data

• Hazardous Substances Data: 842144-06-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(E)-7-bromo-4-chloro-1-ethyl-N-hydroxy-1H-imidazo[4,5-c]pyridine-2-carbimidoyl cyanide is used as a research compound for its potential biological activity. Its unique structure and functional groups make it a promising candidate for the development of new pharmaceuticals, particularly those targeting specific biological pathways or receptors.
Used in Organic Synthesis:
In the field of organic chemistry, (E)-7-bromo-4-chloro-1-ethyl-N-hydroxy-1H-imidazo[4,5-c]pyridine-2-carbimidoyl cyanide serves as a starting material for the synthesis of other complex organic compounds. Its multiple functional groups provide opportunities for further chemical reactions and modifications, leading to the creation of novel molecules with specific properties and applications.
Used in Chemical Process Development:
(E)-7-broMo-4-chloro-1-ethyl-N-hydroxy-1H-iMidazo[4,5-c]pyridine-2-carbiMidoyl cyanide's complex nature and multiple functional groups make it a valuable tool in the development of new chemical processes. It can be used to study reaction mechanisms, optimize reaction conditions, and develop new methodologies for the synthesis of related compounds or the functionalization of other molecules.
Used in Material Science:
(E)-7-bromo-4-chloro-1-ethyl-N-hydroxy-1H-imidazo[4,5-c]pyridine-2-carbimidoyl cyanide may also find applications in material science, particularly in the design and synthesis of new materials with specific properties. Its structural features could be exploited to create materials with unique electronic, optical, or mechanical characteristics, depending on the desired application.

Upstream product

• 842144-05-2 (7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 

Downstream Products

• 842144-07-4 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine 

Relevant articles and documents

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.

INHIBITORS OF Akt ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.